Goldberg
Law PC (http://www.Goldberglawpc.com)
announces that it is investigating claims of potential
misrepresentations by QRx Pharma, Ltd. (“QRx” or the “Company”) (OTC: QRXPY)
(OTC: QRXPF).
The investigation focuses on whether the Company and its officers
violated securities laws by issuing misleading information to investors.
If you purchased or otherwise acquired QRx shares and would like more
information regarding the investigation, we advise you to contact Michael
Goldberg or Brian Schall,
of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey,
CA 90292, at 800-977-7401, to discuss your rights without cost to you.
You can also reach us through the firm’s website at http://www.Goldberglawpc.com,
or by email at info@goldberglawpc.com.
The investigation concerns whether the Company violated the Securities
Exchange Act of 1934. Specifically, the investigation will focus on
whether the Company failed to disclose to investors that it received a
"no agreement letter" from the Food and Drug Administration ("FDA")
regarding its Moxduo trials. When the truth was revealed, shares dropped
causing investors harm.
If you have any questions concerning your legal rights in this case,
please immediately contact Goldberg Law PC at 800-977-7401, or visit our
website at http://www.Goldberglawpc.com,
or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes
in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150813006471/en/
Copyright Business Wire 2015